Scioto Biosciences to Present at Microbiome Movement – Maternal & Infant Health Summit in Boston

INDIANAPOLIS–(BUSINESS WIRE)–Scioto
Biosciences, a preclinical stage company developing next generation
microbiome therapeutics, today announced that it will present at the Microbiome
Movement – Maternal & Infant Health Summit held
on May 22-24^th at the Revere Boston Common Hotel.

Dr. Mark Heiman, Chief Scientific Officer of Scioto will give a talk on
May 24^th at 9:30 a.m., titled “Spontaneous Weaning of Rat
Pups is Stimulated by SB-121 – mediated Gut Development,” which will
highlight the company’s unique live bacterial therapeutic platform
formulation SB-121 and its benefits in promoting the development of a
healthy infant microbiome. By delivering live bacteria in the activated
state, Scioto’s platform promotes colonization and provides lasting
beneficial effects of the active bacteria lactobacillus reuteri.
Studies in premature animals have shown the ability to alter the
microbiome and provide enhanced efficacy with just a single dose of
bacteria.

“Our novel Activated Bacterial Therapeutic (ABT) delivery platform
provides enhanced function for live bacterial therapeutics. This will be
a tremendous benefit to patients, including the neonatal population,”
explained Heiman. “With this unique platform, we can take an
off-the-shelf, commensal bacteria like lactobacillus reuteri and
create a pipeline to treat multiple patient populations.”

Microbiome Movement – Maternal & Infant Health Summit is the
industry-leading forum that focuses exclusively on the development and
commercialization of microbiome-based therapeutics for Maternal & Infant
Health; with case-studies from target discovery all the way through to
clinical trial development, manufacturing and beyond.

About Scioto Biosciences

Based in Indianapolis, Scioto Biosciences is a preclinical stage company
developing innovative therapies devoted to having a transformative impact
on the delivery of live bacterial therapeutics (LBTs). Scioto was
founded in 2017 as a partnership between Indiana business accelerator, Monon
Bioventures (MBV) and The
Research Institute at Nationwide Hospital (RINCH), with whom the
company has a worldwide exclusive licensing agreement. The Scioto ABT
delivery platform has the potential to enhance efficacy wherever LBTs
are used such as metabolic disease, neurological disorders,
gastrointestinal health, alternatives to in-feed antibiotics (in
livestock) and others. For more information, visit http://sciotobiosciences.com/.

Contacts

LaVoieHealthScience
Katie Gallagher, 617-374-8800 x109
[email protected]